JPRN-UMIN000030082
Completed
未知
Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma. - Long term follow-up study of gefitinib vs erlotinib for lung adenocarcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Previously treated advanced lung adenocarcinoma
- Sponsor
- West Japan Oncology Group
- Enrollment
- 561
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
Completed
Not Applicable
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)on-small cell lung cancerJPRN-UMIN000006340orth-East Japan Study Group345
Unknown
Not Applicable
A phase II study of gefitinib in PS3 (4) advanced adenocarcinoma of the lungPS 3 patients (or PS 4 patients because of bone or brain metastasis) with advanced adenocarcinoma of the lung.JPRN-C000000187Department of Medical Oncology, Kinki University School of Medicine30
Completed
Phase 2
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
Completed
Phase 2
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33